Correspondence 0001213900-24-099726 from Athena Technology Acquisition Corp. II (ATEK, ATEKW) (CIK 0001882198) (ATEK)
Athena Technology Acquisition Corp. II (ATEK, ATEKW) (CIK 0001882198)
Date: Nov. 18, 2024 · CIK: 0001882198 · Accession: 0001213900-24-099726
AI Filing Summary & Sentiment
File numbers found in text: 001-41144
Referenced dates: November 15, 2024
Show Raw Text
CORRESP
1
filename1.htm
330 North Wabash Avenue
Suite 2800
Chicago, Illinois 60611
330 North Wabash Avenue
Tel: +1.312.876.7700 Fax: +1.312.993.9767
www.lw.com
FIRM / AFFILIATE OFFICES
Austin
Milan
Beijing
Munich
Boston
New York
Brussels
Orange County
Century City
Paris
Chicago
Riyadh
November 18, 2024
Dubai
San Diego
Düsseldorf
San Francisco
VIA EDGAR
Frankfurt
Seoul
Hamburg
Silicon Valley
United States Securities and Exchange Commission
Hong Kong
Singapore
Division of Corporation Finance
Houston
Tel Aviv
Office of Trade & Services
London
Tokyo
100 F Street, N.E.
Los Angeles
Washington, D.C.
Washington, D.C. 20549-6010
Madrid
Attention:
Pearlyne Paulemon, Brigitte Lippmann
Re:
Athena Technology Acquisition
Corp. II
Preliminary Proxy Statement on
Schedule 14A
Filed November 4, 2024
File No. 001-41144
Ladies
and Gentlemen:
On
behalf of our client, Athena Technology Acquisition Corp. II (the “Company”), set forth below is the Company’s
response to the comment of the staff (the “Staff”) of the Securities and Exchange Commission in their letter dated
November 15, 2024 relating to the Company’s Preliminary Proxy Statement on Schedule 14A filed on November 4, 2024 (the “Proxy
Statement”). Concurrently with the submission of this letter, the Company has publicly filed Amendment No. 1 on Schedule 14A
(“Amendment No. 1”), which reflects the revisions described herein and certain other updated information.
For
ease of reference, the text of the comment in the Staff’s letter has been reproduced in italics herein, with the Company’s
response immediately following. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in Amendment
No. 1.
Preliminary
Proxy Statement on Schedule 14A
Risk Factors,
page 22
1. We
note that you are seeking to extend your termination date to September 14, 2025, a date which
is 45 months from your initial public offering. We also note that you are currently listed
on the NYSE American and Section 119(b) of the NYSE American Company Guide requires that
a special purpose acquisition company complete a business combination within 36 months of
the effectiveness of its IPO registration statement. Please revise your disclosure regarding
a right to appeal a delisting to conform with your language on page 23 that states that your
securities will face immediate suspension and delisting action once you receive a delisting
determination letter from the NYSE American after the 36-month window ends on December 10,
2024. See Section 119(f) of the NYSE American Company Guide. In addition, disclose that as
a consequence of any such suspension or delisting, you may no longer be attractive as a merger
partner.
Response:
In response to the Staff’s comment, the Company respectfully advises the Staff that it has revised the disclosure on page 23 of
Amendment No. 1 to reflect that the NYSE American suspension and delisting action are subject to an appeal pursuant to Part 12 of the
NYSE American Company Guide. Further, the Company has revised the disclosure on pages 22 and 23 of Amendment No. 1 to note that any such
suspension or delisting may cause the Company to be unable to attract a merger partner.
* * *
November
18, 2024
Page 2
Should
you have any comments or questions regarding the foregoing, please call me at (312) 876-7605 or e-mail me at scott.westhoff@lw.com, or
Peyton Worley at (212) 906-1282 or peyton.worley@lw.com. Thank you in advance for your attention to this matter.
Very truly yours,
cc:
Peyton Worley,
Latham & Watkins LLP
/s/
Scott W. Westhoff
Scott
W. Westhoff
of
LATHAM & WATKINS LLP